Intensive Studies for Recertification: Pharmacotherapy (Cert #L199018)

ACPE Numbers:
0204-9999-18-227-H01-P
0204-0000-18-289-H01-P
0204-0000-18-251-H01-P
0204-9999-18-322-H01-P


Release Date: 02/06/2019
Expiration Date: 08/06/2019
Activity Type: Application-based
CE Credits: 6 hours
Activity Fee: $100 (ASHP member); $150 (non-member) 

Accreditation for Pharmacists

 The American Society of Health-System Pharmacists and the American Pharmacists Association (APhA) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

These activities were recorded during a live educational event on December 3-5, 2018 at the Midyear Clinical Meeting in Anaheim, California. Learners who claimed credit for the live activities should not claim credit for these home study activities. 

Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Anticoagulation
  • Antidiabetic drug therapy
  • Drug therapy for cardiovascular disease
  • Pharmacogenomics 

Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pharmacotherapy. 

The Pharmacotherapy  Intensive Study for Recertification Package consists of 4 activities (see table below) recorded during a live educational event on December 3-5, 2018 at the Midyear Clinical Meeting in Anaheim, Californiaand provides up to 6 hours of continuing pharmacy education and/or recertification credit.                                                                                                                                                                                   

These activities are part of the ASHP professional development program for BCPS recertification approved by the BPS. For pharmacists who maintain more than one certification, three of the activities are approved for multiple specialties(see table below). 

Recertification Credit*

Board certified pharmacists are eligible to receive up to 6 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Participants who pass the assessments between February 6, 2019 - August 6, 2019, will be eligible for recertification credit for 2019.

Learning Module

ACPE Number

Credit Hours

Specialty

*Assessment Pass Point

Expanding the Roles of Clinical Pharmacogenomics and Its Implementation*

0204-9999-18-227-H01-P

1.5

BCACP, BCCCP, BCGP, BCPPS, BCPS

71%

Current Concepts: The Application of Cardiovascular Pharmacogenomics in Clinical Practice

0204-0000-18-289-H01-P

1

BCPS

80%

Individualizing Anticoagulation in the Acutely Ill: A Case-Based Approach

0204-0000-18-251-H01-P

1.5

BCCCP, BCPS

71%

Examining the Influence of Cardiovascular Outcome Trials: Is It the Heart of Diabetes?*

0204-9999-18-322-H01-P

2

BCACP, BCPS

76%

 

Learning Objectives


Expanding the Roles of Clinical Pharmacogenomics and Its Implementation
*
0204-9999-18-227-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Recommend the key steps in the implementation of pharmacogenetics testing in clinical practice.
  • Evaluate strategies to initiate pharmacogenetic testing at your organization.
  • Given a case study, evaluate key elements of a pharmacogenomics testing product.
  • Given a case study, recommend appropriate pharmacogenomics resources based on specific needs in the implementation process.

This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP), Board Certified Critical Care Pharmacist (BCCCP), Board Certified Geriatric Pharmacist (BCGP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Current Concepts: The Application of Cardiovascular Pharmacogenomics in Clinical Practice"
0204-0000-18-289-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Evaluate the results of pharmacogenomic tests and apply the results to a cardiovascular patient case.
  • Given a case, use evidence-based guidelines and literature to formulate a cardiovascular patient-specific medication plan based on pharmacogenomic test results and other patient-specific factors.
  • Recommend strategies for the implementation of pharmacogenomics in cardiovascular pharmacy practice.

This activity is approved for Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Individualizing Anticoagulation in the Acutely Ill: A Case-Based Approach
0204-0000-18-251-H01-P

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Identify unique characteristics of acutely ill patients that influence the approach to anticoagulation.
  • Develop and implement an acute anticoagulation strategy for an acutely ill patient.
  • Given a patient case, design a revised anticoagulation regimen and a follow-up assessment plan for an acutely ill patient.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit. 

Examining the Influence of Cardiovascular Outcome Trials: Is It the Heart of Diabetes?*
0204-9999-18-322-H01-P

  • Evaluate the potential benefits of antidiabetic therapy beyond A1C lowering effects.
  • Given a case study, analyze the results from antidiabetic therapy cardiovascular outcome clinical trials (CVOT).
  • Given a case study, design an individualized, evidence-based pharmacotherapeutic plan for a patient with type 2 diabetes.
  • Given a scenario, recommend strategies for identifying and integrating into practice the results of new CVOT literature involving antidiabetic drug therapy.

This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP) and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Faculty

Christina Aquilante, Pharm.D., FCCP
Professor
University of Colorado
Aurora, Colorado 

Gillian C. Bell, Pharm.D.
Interim Director, Personalized Medicine
Mission Health
Asheville, North Carolina 

William Dager, Pharm.D., BCPS, FASHP, FCCM, FCCP, MCCM
Pharmacist Specialist
University of California, Davis Medical Center
Sacramento, California 

Henry Dunnenberger, Pharm.D., BCPS
Director, Pharmacogenomics
NorthShore University HealthSystem
Evanston, Illinois 

Michael P. Gulseth, Pharm.D., BCPS, FASHP
Program Director for Anticoagulation Services
Sanford USD Medical Center
Sioux Falls, South Dakota 

Melody Hartzler, Pharm.D., AE-C, BCACP, BC-ADM
Clinical Pharmacist and Chronic Care Management Coordinator
Western Medicine, Inc.
Fairborn, Ohio

Kristi W. Kelley, Pharm.D., BCACP, BC-ADM, BCPS, CDE
Clinical Professor, Pharmacy Practice
Clinical Pharmacist
Auburn University Harrison School of Pharmacy and Continuity of Care Internal
Clinical Pharmacist
Baptist Health, Inc.
Birmingham, Alabama 

Content Matter Experts

Christopher Betz, Pharm.D., BCPS, FASHP, FKSHP
Professor, Clinical and Administrative Sciences
Sullivan University College of Pharmacy
Louisville, Kentucky 

Snehal H. Bhatt, Pharm.D., BCPS
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts 

Angela L. Bingham, Pharm.D., BCCCP, BCNSP, BCPS
Associate Professor of Clinical Pharmacy
Philadelphia College of Pharmacy – University of the Sciences
Philadelphia, Pennsylvania
Clinical Pharmacy Specialist
Cooper University Hospital
Camden, New Jersey 

Bradley Burton, Pharm.D., BCOP
Clinical Pharmacy Specialist-Medical Oncology
The Johns Hopkins Hospital
Baltimore, Maryland

Kelly Epplen, Pharm.D., B.S.Pharm., BCACP, FASHP
Associate Professor of Clinical Pharmacy Practice
The James L. Winkle College of Pharmacy
University of Cincinnati
Cincinnati, Ohio 

Stuart T. Haines, Pharm.D., BCACP, BC-ADM, BCPS
Professor, Department of Pharmacy Practice
Director, Pharmacy Professional Development
University of Mississippi College of Pharmacy
Jackson, Mississippi 

Peter N. Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
Associate Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Adjunct Associate
University of Oklahoma - College of Medicine
Oklahoma City, Oklahoma 

Ali Roberts, Pharm.D., BCPS
Medical Science Liaison II
Guardant Health
Redwood City, California 

Maria Shin, Pharm.D., BCGP, BCPS
Assistant Professor
Sullivan University College of Pharmacy
Louisville, Kentucky 

Douglas Slain, Pharm.D., BCPS-AQ ID, FASHP, FCCP
Associate Professor and Infectious Diseases Clinical Specialist
West Virginia University School of Pharmacy
Morgantown, West Virginia 

Paul M. Szumita, Pharm.D., BCCCP, BCPS, FASHP, FCCM
Clinical Pharmacy Practice Manager
Brigham and Women's Hospital
Foxboro, Massachusetts 

Reviewers

Holly L. Byrnes, Pharm D., BCPS
Susan R. Dombrowski, M.S., R.Ph.
Kristi Hofer, Pharm.D.
Robert Tremmel, Pharm.D., R.Ph. 

Field Tester

Ahmed Ali, BCPS
Shannon Allcron, Pharm.D., BCCCP, BCPS
Steven Asbill, Pharm.D., BCPS
Jennifer Banks, Pharm.D, BCACP, BCGP, BCPS, BC-ADM, CDE
Monica Bogenschutz, Pharm.D, BCPPS, BCPS
Agnes Cha, Pharm.D., BCACP, AAHIVP
Heather Dedman, B.Sc., BCPPS, BSP
Elizabeth Claire Elson, Pharm.D., BCPPS
Nicholas Farina, Pharm.D., BCCCP
Brian Ferullo, Pharm.D., BCGP
Jacqueline Finger, Pharm.D., BCCCP
Michael Ganio, Pharm.D., M.S., BCPS
Amy Holmes, Pharm.D., BCPPS
Julia Lau, Pharm.D., BCPS
Suwen Lim, M.ClinPharm, BCACP, BCGP, BCOP, BCPS
Monica Mahoney, Pharm.D., BCIDP, BCPS
Sana Mandal, Pharm.D. BCPS
Taryn Mondiello, Pharm.D., BCACP
Rui Yi Neo, BCPS
Frances Ngok, Pharm.D., BCACP, CDE
Roger Pritchard, Pharm.D., BCACP
Gehad Ramadan, BCPS
Amira Shahin, BCPS
Zachary Smith, Pharm.D., BCCCP, BCPS
Mahmoud Tammam, BCPS
ColleenTeevan, Pharm.D., BCCCP, BCPS
Peter Ty, Pharm.D., BCCCP, BCPS
Agnes Vitarini, Pharm.D., BCGP, BCPS
Alan Zhao, Pharm.D., BCPS, BCCCP
Juliana Zschoche, Pharm.D., BCPS             

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • Henry Dunnenberger
    • Admera Health - Consultant, Honorarium
    • Veritas Genetics - Consultant
  • Michael P. Gulseth
    • BMS - Advisory Board, Speakers Bureau
    • Janssen - Speakers Bureau
    • Pfizer - Speakers Bureau
    • Portola - Advisory Board, Speakers Bureau
  • Melody Hartzler
    • Janssen – Speakers Bureau
    • Valeritas – Speakers Bureau
  • All other presenters, program chairs, planners, reviewers, staff, and others with an opportunity to control CE content, have nothing to disclose.

    Methods and CE Requirements

    Activities consist of audio/ video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

    Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

    System Technical Requirements

    Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

    View the minimum technical and system requirements for learning activities. 

    Development

    *These activities were developed in partnership between ASHP and the American Pharmacists Association (APhA).